Manchester Pharmaceuticals has reported the availability of Chenodal 250mg(chenodiol tablets). The FDA has approved Chenodal for patients suffering from gallstones, in whom, surgery poses an unacceptable health risk due to disease or advanced age.
Reportedly, Chenodal prescriptions have started to be dispensed to patients exclusively through Centric Health Resources (Centric). Centric provides a single point of contact to deliver support for Chenodal including providing necessary information to health care providers, patients and families, assisting with reimbursement and insurance issues, and ensuring that Chenodal reaches the patients.
Lloyd Glenn, president of Manchester Pharmaceuticals, said: “The commercial availability of Chenodal now provides doctors and their patients with a chenodiol product that meets all FDA requirements for product integrity, quality, safety and effectiveness.”